Preliminary experience with yttrium-90-labeled Rituximab (chimeric anti-CD20 antibody) in patients with relapsed and refractory B-cell NHL - a prospective trial

被引：0
|
作者：
Thakral, P. [1 ]
Lata, S. [1 ]
Singla, S. [1 ]
Sharma, A. [1 ]
Bal, C. [1 ]
Malhotra, A. [1 ]
机构：
[1] All India Inst Med Sci, New Delhi, India
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2012年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP690
引用
收藏
页码：S294 / S294
页数：1
相关论文
共 50 条
  • [41] B-cell depletion in patients with multiple myeloma with the anti-CD20 monoclonal antibody rituximab after high dose therapy
    Witzens, M
    Gemmel, C
    Moos, M
    Goldschmidt, H
    Ho, AD
    BONE MARROW TRANSPLANTATION, 1999, 23 : S141 - S141
  • [42] Mechanism of action on B cell lymphoma by chimeric anti-CD20 monoclonal antibody
    T Oyama
    Y Kagami
    M Seto
    Y Morishima
    Leukemia, 2001, 15 : 1667 - 1667
  • [43] Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-CD20 monoclonal antibody rituximab
    Pickartz, T
    Ringel, F
    Wedde, M
    Renz, H
    Klein, A
    von Neuhoff, N
    Dreger, P
    Kreuzer, KA
    Schmidt, CA
    Srock, S
    Schoeler, D
    Schriever, F
    EXPERIMENTAL HEMATOLOGY, 2001, 29 (12) : 1410 - 1416
  • [44] Mechanism of action on B cell lymphoma by chimeric anti-CD20 monoclonal antibody
    Oyama, T
    Kagami, Y
    Seto, M
    Morishima, Y
    LEUKEMIA, 2001, 15 (10) : 1667 - 1667
  • [45] Durable remission in recurrent T-cell-rich B-cell lymphoma with the anti-CD20 antibody rituximab
    Natkunam, Y
    Stanton, TS
    Warnke, RA
    Horning, SJ
    CLINICAL LYMPHOMA, 2001, 2 (03): : 185 - 187
  • [46] A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia
    Saleh, MN
    Gutheil, J
    Moore, M
    Bunch, PW
    Butler, J
    Kunkel, L
    Grillo-López, AJ
    LoBuglio, AF
    SEMINARS IN ONCOLOGY, 2000, 27 (06) : 99 - 103
  • [47] Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus
    Iwata, S.
    Saito, K.
    Hirata, S.
    Ohkubo, N.
    Nakayamada, S.
    Nakano, K.
    Hanami, K.
    Kubo, S.
    Miyagawa, I.
    Yoshikawa, M.
    Miyazaki, Y.
    Yoshinari, H.
    Tanaka, Y.
    LUPUS, 2018, 27 (05) : 802 - 811
  • [48] A novel platform for radioimmunotherapy.: Extracorporeal depletion of biotinylated and 90Y-labeled anti-CD20 in patients with refractory B-cell lymphoma.
    Linden, O
    Kurkus, J
    Garkavij, M
    Cavallin-Ståhl, E
    Ohlsson, T
    Nilsson, R
    Sandberg, BE
    Ljungberg, M
    Strand, SE
    Tennvall, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 576S - 576S
  • [49] Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody
    Tsai, DE
    Maillard, I
    Schuster, SJ
    Nasta, SD
    Porter, DL
    Klumpp, TR
    Goldenberg, DM
    Luger, SM
    Alavi, A
    Sharkey, RM
    Hartzell, KB
    Stadtmauer, EA
    CLINICAL LYMPHOMA, 2003, 4 (01): : 56 - 59
  • [50] Experimental treatment of human diffuse large B-cell lymphoma xenografts by doxycycline alone or in combination with the anti-CD20 chimeric monoclonal antibody rituximab
    Assayag, Franck
    Brousse, Nicole
    Couturier, Jerome
    Macintyre, Elizabeth
    Mathiot, Claire
    Dewulf, Sebastien
    Froget, Benoit
    Vincent-Salomon, Anne
    Decaudin, Didier
    AMERICAN JOURNAL OF HEMATOLOGY, 2009, 84 (06) : 387 - 388
12345